Treatment of malignant hypercalcaemia with clodronate.
We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8-3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppressed for the duration of treatment, but recurred promptly when treatment was stopped. Clodronate may be a useful measure for controlling hypercalcaemia and osteolysis in patients with carcinoma.
Percival
R C
RC
Paterson
A D
AD
Yates
A J
AJ
Beard
D J
DJ
Douglas
D L
DL
Neal
F E
FE
Russell
R G
RG
Kanis
J A
JA
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary*; D002118:Calcium / Q000097:blood / Q000652:urine; D004002:Clodronic Acid / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010014:Osteolysis / Q000188:drug therapy
D004164:Diphosphonates; D004002:Clodronic Acid; D003404:Creatinine; D000469:Alkaline Phosphatase; D002118:Calcium